Truist initiated coverage of Tectonic Therapeutic (TECX) with a Buy rating and $64 price target Tectonic is advancing lead relaxin asset, TX45 for Group 2 pulmonary hypertension-heart failure with preserved ejection fraction and Truist is cautiously optimistic that TX45 will be successful in its ongoing Phase 2 study, the analyst tells investors in a research note. Truist likes the current risk-reward.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECX: